Comparison of the effects of quinapril and irbesartan on P-wave dispersion in hypertensive patients

Advances in Therapy

Volumn 25, Issue 8, 2008, Pages 775-786

  Guntekin, Unal ^a   Gunes, Yilmaz ^a   Tuncer, Mustafa ^a   Simsek, Hakki ^a   Gunes, Ahmet ^b  

^a YUZUNCU YIL UNIVERSITY   (Turkey)

^b Urfa Kalp Merkezi   (Turkey)

Author keywords

Atrial fibrillation; Irbesartan; P wave dispersion; Quinapril

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BIPHENYL DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; QUINAPRIL; TETRAHYDROISOQUINOLINE DERIVATIVE; TETRAZOLE DERIVATIVE;

ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ELECTROCARDIOGRAPHY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ATRIAL FIBRILLATION; BIPHENYL COMPOUNDS; BLOOD PRESSURE; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; TETRAHYDROISOQUINOLINES; TETRAZOLES;

EID: 58749088068     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-008-0083-1     Document Type: Article

References (43)

1. Roithinger FX, Karch MR, Steiner PR, et al. The spatial dispersion of atrial refractoriness and atrial fbrillation vulnerability. J Interv Card Electrophysiol. 1999;3:311-319.
2. Michelucci A, Giuseppe B, Colella A, et al. P wave assessment: statement of the art update. Card Electrophys Rew. 2002;6:215-220. (Pubitemid 35276929)
3. Ciaroni S, Cuenoud L, Bloch A. Clinical study to investigate the predictive parameters for the onset of atrial fbrillation in patients with essential hypertension. Am Heart J. 2000;139:814-819. (Pubitemid 30305402)
4. Tukek T, Akkaya V, Atilgan D, et al. Effect of lef atrial size and function on P-wave dispersion: a study in patients with paroxysmal atrial fbrillation. Clin Cardiol. 2001;24:676-680. (Pubitemid 32923780)
5. Ozer N, Aytemir K, Atalar E, et al. P wave dispersion in hypertensive patients with paroxysmal atrial fbrillation. Pacing Clin Electrophysiol. 2000;23(11 pt 2):1859-1862.
6. Dilaveris PE, Gialafos EJ, Chrissos D, et al. Detection of hypertensive patients at risk for paroxysmal atrial fbrillation during sinus rhythm by computer-assisted P wave analysis. J Hypertens. 1999;17:1463-1470. (Pubitemid 29509493)
7. Wijfels M, Kirchhof C, Dorland R, Alessie M. Atrial fbrillation begets atrial fbrillation: a study in awake chronically instrumented goats. Circulation. 1995;92:1954-1968.
8. Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, Arakawa K. Angiotensin II antagonist prevents electrical remodeling in atrial fbrillation. Circulation. 2000;101:2612-2617. (Pubitemid 30350640)
9. Li D, Shinagawa K, Pang L, et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fbrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation. 2001;104:2608-2614. (Pubitemid 33104801)
10. Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fbrillation. J Am Coll Cardiol. 2003;41:2197-2204. (Pubitemid 36724267)
11. Shi Y, Li D, Tardif JC, Nattel S. Enalapril Effects on atrial remodeling and atrial fbrillation in experimental congestive heart failure. Cardiovasc Res. 2002;54:456-461. (Pubitemid 34327924)
12. Tsang TSM, Barnes ME, Abhayaratna WP, et al. Effects of quinapril on lef atrial structural remodeling and arterial stifness. Am J Cardiol. 2006;97:916-920.
13. Madrid AH, Marin IM, Cervantes CE, et al. Prevention of recurrences in patients with lone atrial fbrillation. The dose-dependent Effect of angiotensin II receptor blockers. J Renin Angiotensin Aldosterone Syst. 2004;5:114-120. (Pubitemid 39406720)
14. Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Circulation. 2006;114:e84-e231. (Pubitemid 44268973)
15. Pickering TG. Blood pressure measurement issues. In: Oparil S, Weber MA, eds. Hypertension: a Companion to Brenner and Rector's the Kidney. Philadelphia: WB Saunders; 2000:306-313.
16. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantifcation: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantifcation Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440-1463. (Pubitemid 41821197)
17. Dogan A, Ozaydin M, Nazli C, et al. Does impaired lef ventricular relaxation afect P wave dispersion in patients with hypertension? Ann Noninvasive Electrocardiol. 2003;8:189-193. (Pubitemid 38569975)
18. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fbrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005;45: 1832-1839. (Pubitemid 40789940)
19. Ehrlich JR, Hohnloser SH, Nattel S. Role of angiotensin system and Effects of its inhibition in atrial fbrillation: clinical and experimental evidence. Eur Heart J. 2006;27:512-518.
20. Goette A, Staack T, Rocken C, et al. Increased expression of extracellular signal regulated kinase and angiotensin-converting enzyme in human atria during atrial fbrillation. J Am Coll Cardiol. 2000;35:1669-1677. (Pubitemid 30307515)
21. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fbrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol.;48:e149-e246.
22. Johnston CI, Jandeleit K, Mooser V, et al. Angiotensin-converting enzyme and its inhibition in the heart and vessels. J Cardiovasc Pharmacol. 1992;20:6-12.
23. Adams MA, Trudeau L. Irbesartan: review of pharmacology and comparative properties. Can J Clin Pharmacol. 2000;7:22-31. (Pubitemid 30232667)
24. L'Allier PL, Ducharme A, Keller PF, Yu H, Guertin MC, Tardif JC. Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fbrillation. J Am Coll Cardiol. 2004;44:159-164. (Pubitemid 38976480)
25. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fbrillation and subsequent stroke compared to atenolol: the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45:712-719. (Pubitemid 40282586)
26. Vermes E, Tardif JC, Bourassa MG, et al. Enalapril decreases the incidence of atrial fbrillation in patients with lef ventricular dysfunction: insight from the Studies Of Lef Ventricular Dysfunction (SOLVD) trials. Circulation. 2003;107:2926-2931. (Pubitemid 36736634)
27. Maggioni AP, Latini R, Carson PE, et al. Valsartan reduces the incidence of atrial fbrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J. 2005;149:548-557. (Pubitemid 40585420)
28. Ducharme A, Swedberg K, Pfefer MA, et al. Prevention of atrial fbrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Am Heart J. 2006;151:985-991.
29. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fbrillation afer acute myocardial infarction in patients with lef ventricular dysfunction. Circulation. 1999;100:376-380. (Pubitemid 29362407)
30. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354:1751-1756.
31. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611-616. (Pubitemid 29087980)
32. Connolly S, Yusuf S, Budaj A, et al. Rationale and design of ACTIVE: the atrial fbrillation clopidogrel trial with irbesartan for prevention of vascular events. Am Heart J. 2006;151:1187-1193.
33. Teo K, Yusuf S, Sleight P, et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Te lmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J. 2004;148:52-61. (Pubitemid 38906646)
34. Lopez B, Querejeta R, Varo N, et al. Usefulness of serum carboxy-terminal propeptide of procollagen type 1 in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation. 2001;104:286-291. (Pubitemid 32666949)
35. Klein HU, Goette A. Blockade of atrial angiotensin II type 1 receptors: a novel antiarrhythmic strategy to prevent atrial fbrillation. J Am Coll Cardiol. 2003;41:2205-2206. (Pubitemid 36724268)
36. Ueng KC, Tsai TP, Yu WC, et al. Use of enalapril to facilitate sinus rhythm maintenance afer external cardioversion of long-standing persistent atrial fbrillation. Results of a prospective and controlled study. Eur Heart J. 2003;24:2090-2098.
37. Yin Y, Dalal D, Liu Z, et al. Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fbrillation recurrence in patients with lone paroxysmal atrial fbrillation. Eur Heart J. 2006;15:1841-1846. (Pubitemid 44297391)
38. Tveit A, Grundvold I, Olufsen M, et al. Candesartan in the prevention of relapsing atrial fbrillation. Int J Cardiol. 2007;120:85-91. (Pubitemid 47008995)
39. Dilaveris PE, Gialafos EJ, Sideris SK, et al. Simple electrocardiographic markers for the prediction of paroxysmal idiopathic atrial fbrillation. Am Heart J. 1998;135:733-738. (Pubitemid 28237295)
40. Aytemir K, Ozer N, Atalar E, et al. P wave dispersion on 12 lead electrocardiography in patients with paroxysmal atrial fbrillation. Pacing Clin Electrophysiol. 2000;23: 1109-1112. (Pubitemid 30480158)
41. Celik T, Iyisoy A, Kursaklioglu H, et al. The comparative Effects of telmisartan and ramipril on P wave dispersion in hypertensive patients: a randomized clinical study. Clin Cardiol. 2005;28:298-302. (Pubitemid 40803516)
42. Tukek T, Akkaya V, Demirel S, et al. Effect of valsalva maneuver on surface electrocardiographic P wave dispersion in paroxysmal atrial fbrillation. Am J Cardiol. 2000;85:896-899. (Pubitemid 30157863)
43. Dilaveris PE, Gialafos JE. P-wave duration and dispersion analysis: methodological considerations. Circulation. 2001;103:e111.